What is the role of the R-CHOP chemotherapy regimen in the treatment of mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Another regimen is CHOP plus rituximab (R-CHOP). In a phase 2 randomized trial of CHOP versus R-CHOP in patients with previously untreated MCL, the complete response rate was higher with R-CHOP (34% vs 7%). The time to treatment failure was also in favor of R-CHOP, but the time to progression showed no significant difference. This study was reported by the German Low-Grade Lymphoma Study Group at the 2004 American Society of Clinical Oncology meeting.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!